Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Astellas, sanofi-aventis deal

SAN and Astellas will restructure their Fujisawa sanofi-aventis K.K. JV, which owns the rights

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE